Home › Steatotic Liver Disease › Arkansas
Steatotic Liver Disease clinical trials in Arkansas
8 studies for Steatotic Liver Disease are looking for participants at sites in Arkansas.
Cities in Arkansas
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07701993A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Arkansas Gastroenterology - North Little Rock, North Little Rock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Little Rock
- Akero Clinical Study Site, North Little Rock
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Arkansas Gastroenterology, P.A, Little Rock
- ARcare Center for Clinical Research, Little Rock
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Little Rock
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.